Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
Share
Why It Matters
An expert investor watcher says BridgeBio is a company worth watching and thinks it could do well. This means the expert still believes in the company's future, even though nothing new happened today.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.